In a defiant CNBC interview on Monday, Turning Pharmaceuticals CEO Martin Shkreli defended his decision to raise the price of the AIDS drug Daraprim from $13.50 to $750. Shkreli asserted that the price hike was needed to fund the development of a better HIV drug, even though experts had told CNBC re...